Suzhou Porton Biologics Partners with Future Biotechnology to Expand Viral Vector Services
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd announced this week a...
Cell-therapy
Platinum Life Biotech’s Ruibosheng First Prescribed in China for aGVHD Treatment
Beijing-based Platinum Life Biotech’s Ruibosheng (amimestrocel) has been first prescribed in China, following conditional marketing...
FDA Launches Immediate Review of Clinical Trials Involving Cell Transfer to Hostile Countries
The U.S. Food and Drug Administration (FDA) this week announced an immediate review of new...
CR Sanjiu Partners with HELP Therapeutics to Advance iPSC-based Heart Failure Therapy
China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, announced a partnership with Nanjing-based HELP...
HELP Therapeutics’ iPSC-Derived Cardiomyocyte Therapy Enters US Clinical Trials
Nanjing-based HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, announced that its innovative induced...
JW Therapeutics’ Carteyva Approved by Macau Health Bureau
JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...
JW Therapeutics’ Carteyva Receives Fourth sBLA for r/r LBCL
JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...
AbelZeta Pharma’s C-CAR168 Secures FDA RMAT Designation for Lupus Treatments
Sino-US biotech AbelZeta Pharma, Inc., based in Rockville, Maryland, and with operations in Shanghai, announced...
CARsgen’s Satricabtagene Autoleucel Granted Priority Review by China’s CDE
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that the Center for Drug Evaluation...
CARsgen’s Satri-Cel Shows Significant Efficacy in Gastric Cancer Study
China-based CARsgen Therapeutics Holdings Limited (HKG: 2171) announced that it has published an abstract of...
AstraZeneca Completes Acquisition of EsoBiotec for Up to USD 1 Billion
UK-based major AstraZeneca (AZ; NASDAQ: AZN) announced the completion of its acquisition of EsoBiotec SA,...
Porton and Hualong Biological Partner to Advance MATC Therapy
Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd. has entered into a...
WuHan Hamilton Biotech’s HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure
China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National...
Porton Pharma Collaborates with Henan Hualong for MATC Therapy Development
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions Ltd has entered into a...
Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing
China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer...
Oricell Partners with Umoja Biopharma to Develop In Vivo CAR-T Cell Therapies
China-based Oricell Therapeutics Co., Ltd. announced a strategic partnership agreement with US-headquartered Umoja Biopharma Inc....
EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology
EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series...
BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline
US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) released its Q1 2025 financial results, showing a...
JW Therapeutics Enters Licensing Pact with Juno Therapeutics for sLVV Process
China-based JW Therapeutics (HKG: 2126), co-founded by Juno Therapeutics Inc. (a Bristol-Myers Squibb company) and...
iMBIORAY Gains NMPA Approval for Phase IITrial of IBR854 in Advanced RCC
Hangzhou-based cancer immunotherapy specialist iMBIORAY has received approval from China’s National Medical Products Administration (NMPA)...